Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Electronic Resource  (5)
  • Hodgkin's disease  (4)
  • Abnormal marrow eosinophils  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Therapieergebnisse des Morbus Hodgkin in den Stadien I und II (1981)
    Springer
    Journal of molecular medicine 59 (1981), S. 469-475 
    Details
    ISSN: 1432-1440
    Keywords: Hodgkin's disease ; Treatment results ; Prognostic factors ; Morbus Hodgkin ; Therapieergebnisse ; Prognostische Faktoren
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Behandlungsergebnisse des Morbus Hodgkin der Stadien I und II werden durch Vergleich der Überlebensdaten der Literatur nach verschiedenen Strahlentherapieprogrammen und nach zusätzlicher Chemotherapie diskutiert. Im Stadium I A bleiben 90–97% und im Stadium II A 75–80% der Patienten nach ausgedehnter Strahlentherapie rezidivfrei. Für das Stadium IIB werden 0–80% langdauernde Remissionen nach alleiniger Strahlentherapie berichtet. Zusätzliche Chemotherapie verbessert die Rezidiv-, aber nicht die Überlebenszahlen der Stadien I und II. Gruppen mit hohem Rezidivrisiko (große Mediastinaltumoren, E-Befall der Lunge und lymphozytenarme Histologie) werden dargestellt.
    Notes: Summary The results obtained in the treatment of Hodgkin's disease, stages I and II, are discussed comparing survival data of the literature after various radiotherapy programs and after combined modality using additional chemotherapy. In stage I A 90 to 97% and in stage II A 75 to 80% of patients are not prone to relapse after extended-field irradiation. In stage IIB 0 to 80% long-lasting remissions are reported after radiotherapy. Additional chemotherapy improved relapse-free survival, but not overall survival in stages I and II. Subgroups are discussed which bear a high risk of relapsing disease (big mediastinal masses, E-lesions of the lungs, histological findings with lymphocyte depletion).
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01696208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Behandlungsergebnisse mit dem ABVD-Schema bei C-MOPP-resistentem Morbus Hodgkin (1981)
    Springer
    Journal of molecular medicine 59 (1981), S. 267-273 
    Details
    ISSN: 1432-1440
    Keywords: Hodgkin's disease ; MOPP-failures ; ABVD ; Morbus Hodgkin ; MOPP-Resistenz ; ABVD
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung 22 Patienten wurden mit dem ABVD-Protokoll behandelt. 19 (18 × IV B, 1 × III B) sind auswertbar. Kein Patient mit eingeschränkter, aber 7 von 13 Patienten mit intakter Knochenmarksfunktion erreichten eine Vollremission. Alle vier Patienten mit therapie- und krankheitsfreiem Intervall aber nur von 3 von 13 Patienten ohne freies Intervall erreichten ebenfalls eine Vollremission. Vorbehandlung, Histologie, Dauer der Erkrankung und Lebensalter hatten keinen eindeutigen Einfluß auf die Remissionszahlen. Die Toxizität war insbesondere bei über 50-jährigen Patienten erheblich. Zwei Patienten dieser Altersgruppe brachen die Therapie wegen gastrointestinaler Nebenwirkungen ab und 2 von 8 starben an ABVD-mitverursachten Erkrankungen (1 Leukämie, 1 plötzlicher Herztod). Bei drei Patienten mit hochdosierter Mediastinalbestrahlung war eine Pneumonitis eine der wesentlichen Todesursachen. Nach unseren Ergebnissen ist ABVD ein effektives Chemotherapieprotokoll für einige Subgruppen der „MOPP-Versager“.
    Notes: Summary 22 patients were treated with ABVD, 19 (18 stage IV B 1 stage III B) could be evaluated. No patient with impaired but 7 of 13 patients with intact bone-marrow function achieved a complete remission. A complete remission was also achieved by all 4 patients with a treatment- and disease-free interval but only by 3 of 15 without a free interval. Pretreatment, histology, duration of disease, and age showed no clear prognostic significance with respect to induction of remission. Toxicity was severe especially in patients over 50 years of age. 2 patients discontinued therapy because of gastro-intestinal toxicity. 2 of 8 died of treatment-related causes (1 leukemia, 1 sudden cardiac death). In 3 patients with high-dose mediastinal irradiation a pneumonitis secondary to bleomycin contributed significantly to death. Our results suggest that ABVD is an effective salvageregimen for some subgroups of MOPP-failures.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01478205
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease (1993)
    Springer
    Annals of hematology 66 (1993), S. 251-256 
    Details
    ISSN: 1432-0584
    Keywords: Hodgkin's disease ; High-dose therapy ; Bone marrow transplantation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n=44), autologous BM plus peripheral blood stem cells (PBSC) (n=2), PBSC (n=1), syngeneic (n=1), or allogeneic BM (n=3). All patients had received standard salvage chemotherapy prior to HDT and were classified as sensitive (n=33) or resistant (n=17) to this treatment; one patient was in untreated relapse prior to BMT. The preparative regimens for patients receiving autologous BM and/or PBSC consisted of cyclophosphamide, VP 16, and BCNU (CVB) (n=44) or BCNU, etoposide, ara-C, and melphalan (BEAM) (n=3). The patients receiving allogeneic transplants were treated with the CVB regimen (n=2) or busulfan (16 mg/kg body wt.) and cyclophosphamide (200 mg/kg body wt.). With a median follow-up of 12 months, overall survival for 44 patients grafted with autologous BM is 61%±9%, progression-free survival for patients with sensitive disease is 44%±11%; no patient with resistant relapse survived beyond 1 year post transplant. Two of three patients grafted with allogeneic BM still survive 15 and 24 months after BMT with Karnofsky performance scores of 70% and 100%, respectively. The main toxicity encountered with the CVB regimen was interstitial pneumonia (IP), seen in four of 15 patients (27%) receiving ≥600 mg/m2 of BCNU. Three of these patients have died. The results show that HDT followed by hematopoietic stem cell rescue may effectively salvage an important fraction of patients with relapsed HD who respond to standard chemotherapy. The same approach is largely unsuccessful in patients with proven refractoriness to standard chemotherapy. Whether HDT followed by BMT or PBSC support is superior to intensive chemotherapy without stem cell support can be answered only by a prospectively randomized trial.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01738475
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Prognostic factors in COPP-treated patients with Hodgkin's disease (1982)
    Springer
    Annals of hematology 44 (1982), S. 339-348 
    Details
    ISSN: 1432-0584
    Keywords: Hodgkin's disease ; Risk factors ; Staging system ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In a recently published review of the literature [40] we came to the conclusion that the Ann-Arbor staging classification is of limited prognostic value for chemotherapy of Hodgkin's disease (Table 2). Four risk factors accounted for impaired complete remission rates: stage IVB, lymphocyte depletion or not classifiable histologic type, previous chemotherapy, and older age. Fifty-eight evaluable patients were treated with COPP; 23 reached a complete remission (40%). Disease-free survival was 31%, overall survival 49% after five years [33]. Besides the known risk factors, impaired bone marrow function (leucocyte counts 〈4×109/1, platelet counts 〈100×109/1) at the start of therapy was associated with poor treatment results: none of six patients achieved a complete remission [41]. Eleven of 16 patients with no and 11 of 23 patients with one risk factor achieved a complete remission, as did only one patient with more than one risk factor. Survival rates after 30 months were; 87% with no, 66% with one, 36% with two, and 13% with more than two risk factors. We can conclude from our results that the prognosis of patients undergoing chemotherapy for Hodgkin's disease depends on the number of risk factors.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00319917
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Acute myelomonocytic leukemia with involvement of eosinophils and inversion of chromosome 16 (1984)
    Springer
    Annals of hematology 48 (1984), S. 263-267 
    Details
    ISSN: 1432-0584
    Keywords: Leukemia, acute myelomonocytic ; Abnormal marrow eosinophils ; Chromosome 16
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A case of acute nonlymphocytic leukemia (ANLL) with abnormal marrow eosinophils is presented. Thorough morphological, cytochemical, and cytogenetic studies confirm the existence of a recently defined new cytogeneticmorphological entity: acute myelomonocytic leukemia with abnormal bone marrow eosinophils (FAB M4), chloracetate esterase- and periodic acid-Schiffpositivity of eosinophilic granules, and pericentric inversion of chromosome 16, in this case combined with trisomy 8. So far 18 such cases have been reported from a single institution. The implications of this new association on the diagnosis of acute leukemia with abnormal eosinophils are discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00320396
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...